09:00 AM EST, 11/15/2024 (MT Newswires) -- Boston Scientific ( BSX ) said Friday that it completed the acquisition of Axonics (AXNX), a medical technology company specializing in devices for urinary and bowel dysfunction.

The company said the deal, which has an equity value of $3.7 billion and an enterprise value of $3.3 billion, is expected to be immaterial to adjusted earnings per share in 2024 and 2025 and become accretive afterward.

Boston Scientific ( BSX ) also said that the deal is slated to be less accretive on a GAAP basis due to amortization and acquisition-related costs.

Price: 87.12, Change: -0.47, Percent Change: -0.54